Where should I publish my paper?
Paste your title, abstract or keywords. The finder matches them to research topics and suggests ranked journals that publish most on those topics.
Journals for “Tryptophan and brain disorders”
Suggested journals
Topic match is relative to the best match in this search (100% = best). Fees are shown only where DOAJ records them.
| # | Journal | Topic match | ITS Journal Score | Global rank | Papers 2021–2025 | Open access | Fee (APC) |
|---|---|---|---|---|---|---|---|
| 1 | International Journal of Tryptophan Research SAGE Publishing · United States | 100% | 60.5 | #12,646 | 60 | 100% | Not recorded |
| 2 | Brain Behavior & Immunity - Health Elsevier BV · United States · DOAJ | 73% | 72.7 | #5,303 | 867 | 100% | US$2,500 |
| 3 | Brain Behavior and Immunity Elsevier BV · United States | 59% | 85.3 | #783 | 2,694 | 45% | Not recorded |
| 4 | The World Journal of Biological Psychiatry Taylor & Francis · United Kingdom | 35% | 72.6 | #5,369 | 250 | 35% | Not recorded |
| 5 | Current Neuropharmacology Bentham Science Publishers · The Netherlands | 33% | 76.1 | #3,638 | 884 | 88% | Not recorded |
| 6 | Neurobiology of Stress Elsevier BV · The Netherlands · DOAJ | 33% | 75.1 | #4,068 | 447 | 100% | US$4,230 |
| 7 | Journal of Neuroimmune Pharmacology Springer Science+Business Media · United States | 29% | 78.2 | #2,795 | 291 | 50% | Not recorded |
| 8 | World Journal of Psychiatry Baishideng Publishing Group · United States | 32% | 70.2 | #6,664 | 986 | 100% | Not recorded |
| 9 | Neuropsychiatric Disease and Treatment Dove Medical Press · New Zealand · DOAJ | 29% | 77.2 | #3,185 | 1,317 | 100% | Not recorded |
| 10 | Pharmacological Reports Elsevier BV · Poland | 27% | 77.1 | #3,209 | 615 | 59% | Not recorded |
| 11 | Clinical Psychopharmacology and Neuroscience South Korea | 32% | 66.7 | #8,740 | 426 | 100% | Not recorded |
| 12 | Journal of Neuroinflammation BioMed Central · United Kingdom · DOAJ | 20% | 89.1 | #319 | 1,615 | 100% | 3,490 EUR |
| 13 | General Psychiatry BMJ · United Kingdom · DOAJ | 25% | 76.6 | #3,464 | 352 | 100% | Not recorded |
| 14 | NeuroImmunoModulation Karger Publishers · Switzerland · DOAJ | 30% | 66.5 | #8,901 | 194 | 59% | 2,250 CHF |
| 15 | CNS & Neurological Disorders - Drug Targets Bentham Science Publishers · United Arab Emirates | 27% | 72.1 | #5,624 | 534 | 5% | Not recorded |
| 16 | Complex Psychiatry Karger Publishers · Switzerland | 35% | 56.0 | #15,430 | 65 | 92% | Not recorded |
| 17 | Frontiers in Psychiatry Frontiers Media · Switzerland · DOAJ | 20% | 82.8 | #1,296 | 12,479 | 100% | 3,150 CHF |
| 18 | Biological Psychiatry Elsevier BV · United States | 24% | 76.5 | #3,481 | 6,305 | 19% | Not recorded |
| 19 | ALPHA PSYCHIATRY Türkiye | 30% | 63.0 | #11,005 | 366 | 98% | Not recorded |
| 20 | Metabolic Brain Disease Springer Science+Business Media · United States | 22% | 78.1 | #2,853 | 1,110 | 19% | Not recorded |
| 21 | Translational Psychiatry Springer Nature · United States · DOAJ | 16% | 85.9 | #688 | 2,664 | 100% | 4,190 EUR |
| 22 | Stress Informa · Switzerland · DOAJ | 21% | 74.0 | #4,577 | 210 | 92% | 5,085 AUD |
| 23 | Exploration of Neuroprotective Therapy · DOAJ | 31% | 56.3 | #15,287 | 136 | 100% | Not recorded |
| 24 | Progress in Neuro-Psychopharmacology and Biological Psychiatry Elsevier BV · United States | 16% | 80.4 | #2,028 | 1,154 | 41% | Not recorded |
| 25 | Psychiatry and Clinical Psychopharmacology Taylor & Francis · Türkiye · DOAJ | 25% | 61.0 | #12,335 | 295 | 100% | Not recorded |
| 26 | Therapeutic Advances in Psychopharmacology SAGE Publishing · United Kingdom · DOAJ | 21% | 66.5 | #8,886 | 202 | 100% | US$2,650 |
| 27 | Neuropsychopharmacology Reports Wiley · United States · DOAJ | 21% | 66.0 | #9,193 | 482 | 100% | US$2,500 |
| 28 | IBRO Neuroscience Reports Elsevier BV · United Kingdom · DOAJ | 21% | 66.0 | #9,208 | 2,789 | 100% | US$2,470 |
| 29 | Current Behavioral Neuroscience Reports Springer Science+Business Media · Switzerland | 24% | 57.4 | #14,533 | 88 | 25% | Not recorded |
| 30 | Psychoneuroendocrinology Elsevier BV · United Kingdom | 12% | 78.0 | #2,897 | 1,892 | 44% | Not recorded |
Before you submit
Use this list as a shortlist, not a decision. For each journal, read its aims and scope and a few recent articles, check its peer-review and fee policy on its own website, and confirm any indexing (Scopus, Web of Science, PubMed) with the indexer itself. Be careful with journals that promise very fast acceptance or that contact you by email asking for papers.
How the ITS Journal Score works
One formula applies to every ranked journal, using open data from OpenAlex: 45% citation impact, 35% h-index and 20% size (papers published 2021–2025). Citation impact is the smaller of the journal's two-year mean citedness and its five-year citations per paper, so a journal whose output collapsed cannot jump to the top on old citations. Each part is half a percentile and half a log-scaled value, so the very top is still separated. Growth and open-access share are shown separately and are not part of the score.
A journal is ranked only if it published at least 50 papers in 2021–2025 and was active in at least five of the last six years. Field rankings compare a journal only with journals in the same field; the field is the OpenAlex field with most of the journal's recent papers, or "Multidisciplinary" when no field has 30% of them.
What this is not: the ITS Journal Score is not a Journal Impact Factor, CiteScore or SJR, and this site does not say whether a journal is indexed in Scopus, Web of Science or PubMed. Always confirm aims and scope, indexing, peer review and fees on the journal's own website before you submit.